Mild Cognitive Impairment Clinical Trial
— ThinkingFitOfficial title:
Piloting a Complex Intervention Involving Physical Exercise, Cognitive Training and Socialising to Delay the Onset of Dementia in Mild Cognitive Impairment
Dementia is serious problem and around 700 000 people are affected in the UK alone.
Currently there is no cure however early diagnosis and effective treatment offers hope for
reducing the impact. Dementia sufferers require care due to physical disability, cognitive
deficits, social isolation and emotional symptoms (depression). Delaying the onset of
dementia will improve quality of life for patients and reduce the cost of residential care
(£42 000 per person per year).
People with mild cognitive impairment (MCI) are at high risk of developing dementia. They
have impaired cognitive abilities, such as memory, but still manage their everyday
activities. Studies show that 8 out of 10 people with MCI will have developed dementia 6
years after diagnosis.
Regular physical activities and performing a variety of cognitive activities reduce the risk
of dementia and improves abilities and quality of life in healthy people. Therefore a
combination of these activities may reduce the risk of developing dementia in MCI. The
investigators want to see if they can develop a program which combines these activities in a
fun and social way that gets people active and keeps them active. The aims are to improve
fitness, cognition and quality of life. The investigators plan to use computers and the
internet to help with the activities and to make them available to people who are isolated.
Physical activity will involve walking from home, cognitive activities will be computer
based games and puzzles and socialising will involve regular varied group-based activities.
Participants (128) will be recruited from the UCL Derwent Memory Clinic and will complete a
26 week program. They will then be followed up yearly to monitor their progress. The main
outcome of the study is engagement in the activities. The investigators will also measure
fitness, cognition, quality of life and conversion to dementia.
| Status | Completed |
| Enrollment | 128 |
| Est. completion date | November 2012 |
| Est. primary completion date | November 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 40 Years and older |
| Eligibility |
Inclusion criteria for patients with MCI 1. Patients fulfilling criteria for AMCI [Petersen et al. 2001b]: i. Memory impairment for age and education ii. No impairment in other cognitive domains iii. Normal social activities iv. Patient is not demented 2. For the other subtypes of MCI, cognitive impairment in one or more nonmemory domain 3. Sedentary lifestyle with no regular participation in physical exercise defined as two or three times a week for at least 20 minutes duration, or participation in active sport more than once a week, in the previous six months. 4. Willing and able to give informed consent. 5. Availability and access to safe exercise environments, such as paths or roads with sidewalks for walking or cycling. 6. At low risk from serious adverse effects from increased physical activity as indicated by performance on the revised Physical activity readiness questionnaire (PARQ). Exclusion Criteria: Exclusion criteria for patients with MCI 1. Type 1 (insulin dependent) diabetes mellitus. 2. Blood pressure of 160/100 mmHg or more. 3. Body weight more than 140% of ideal body weight. 4. Musculoskeletal or other medical problems preventing safe participation in regular moderate intensity exercise (65-77% of predicted maximum heart rate). This will include a resting tachycardia (heart rate above 100 bpm) and history of myocardial infarction or unstable angina within the last month. Participants with modifiable exclusion criteria will be reconsidered after successful management. Patients will be referred for medical treatment prior to commencing exercise if indicated by the PARQ and the intervention will be guided by the PARmedX. Participants taking medications affecting heart rate will need to be on a stable dosing regime for 3 months prior to commencing in order to control for potential spurious results on fitness measures caused by these treatments. |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | North Essex Partnership Foundation NHS Trust | Harlow | Essex |
| Lead Sponsor | Collaborator |
|---|---|
| Dr Thomas Dannhauser | University College, London |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Activity Compliance | Number of participants to have completed 50% or more of the programmed activity sessions during the intervention period. | Compliance with programmed activities will be assessed at the end of participation which is expected to be at 24 weeks | No |
| Secondary | Cardiovascular fitness measure | Cardiovascular fitness will be measured with a modified Siconolfi Step Test. | This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks. | Yes |
| Secondary | Cognitive measures | Participants will complete the following cognitive measures: Visual and auditory divided attention task Verbal episodic encoding and recognition task Halstead Trail Making test (TMT) Verbal fluency Working memory tests: digit span forwards/ backwards |
This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks. | No |
| Secondary | Measures of quality of life and everyday activities | Quality of life will be measured on the World Health Organization Quality of Life (WHOQOL) - BREF and change in every day activities on the Alzheimer's Disease Cooperative Study MCI Activities of Daily Living Scale (ADCS-MCI-ADL) | This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks. | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
| Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
| Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
| Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
| Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
| Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
| Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
| Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
| Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
| Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
| Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
| Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
| Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
| Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
| Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
| Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
| Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
| Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
| Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
| Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |